BioNTech SE
BNTX
$100.86
$1.391.40%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -52.12% | -69.09% | -76.63% | -77.64% | -66.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.12% | -69.09% | -76.63% | -77.64% | -66.14% |
| Cost of Revenue | -19.55% | -59.44% | -67.24% | -79.80% | -82.56% |
| Gross Profit | -55.47% | -70.54% | -78.25% | -77.18% | -62.51% |
| SG&A Expenses | 9.49% | 12.07% | 2.47% | 3.25% | -2.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 352.68% | 2,222.57% | -96.98% | -113.06% | -135.71% |
| Total Operating Expenses | 50.78% | 11.03% | -22.51% | -45.54% | -56.32% |
| Operating Income | -122.43% | -114.77% | -104.59% | -92.13% | -70.66% |
| Income Before Tax | -108.92% | -104.42% | -98.29% | -90.79% | -76.19% |
| Income Tax Expenses | -83.24% | -82.16% | -98.63% | -92.72% | -79.04% |
| Earnings from Continuing Operations | -117.67% | -112.20% | -98.16% | -90.07% | -75.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.67% | -112.20% | -98.16% | -90.07% | -75.03% |
| EBIT | -122.43% | -114.77% | -104.59% | -92.13% | -70.66% |
| EBITDA | -117.48% | -111.59% | -102.66% | -91.03% | -69.97% |
| EPS Basic | -117.83% | -112.22% | -98.11% | -89.98% | -74.95% |
| Normalized Basic EPS | -105.67% | -102.99% | -97.51% | -90.35% | -75.75% |
| EPS Diluted | -118.28% | -112.77% | -98.13% | -89.58% | -73.70% |
| Normalized Diluted EPS | -105.93% | -103.22% | -97.51% | -89.97% | -74.57% |
| Average Basic Shares Outstanding | -0.41% | -0.66% | -0.88% | -0.85% | -0.67% |
| Average Diluted Shares Outstanding | -0.91% | -2.28% | -3.99% | -4.94% | -5.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
